


*TM*

*Receipt*



Practitioner's Docket No. MBIO99-057CP2RCEM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Samantha J. Busfield and Jean-Luc Villeval (as amended)  
 Application No.: 09/503,387 Group No.: 1644  
 Filed: February 14, 2000 Examiner: Huynh, Phuong N.  
 For: GLYCOPROTEIN VI AND USES THEREOF

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**TRANSMITTAL**

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (2 pages);
  - b. Request For Corrected Filing Receipt (2 pages);
  - c. Marked-up copy of Corrected Filing Receipt (2 pages);
  - d. Copy of Petition to Amend Inventorship Under 37 C.F.R. 1.48(b), filed September 26, 2002 (2 pages); and
  - e. A Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: October 18, 2006

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MBIO99-057CP2RCEM**

**FEE PAYMENT**

3. Charge Account No. 501668 the sum of \$0.00 (which includes the extension fee and the \$0.00 additional fee for claims). \$0.00

**FEE DEFICIENCY**

4. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

5. Correspondence Address  
Direct all future correspondence to:

**Customer Number 30405**  
**OR**  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139


October 18, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier  
Registration No. 57,225  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/503,387/	02/14/2000	1644	2582	7853-178	30	23	3

### CONFIRMATION NO. 6531

20583  
PENNIE AND EDMONDS  
1155 AVENUE OF THE AMERICAS  
NEW YORK, NY 100362711

### CORRECTED FILING RECEIPT



\*OC000000008903647\*

Date Mailed: 10/03/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Samantha J. Busfield, Cambridge, MA;  
Jean-Luc Villeval, Needham, MA;  
~~Martine Jandrot-Perrus, Vanes, FRANCE;~~  
~~William Vainchencker, Paris, FRANCE;~~

#### Domestic Priority data as claimed by applicant

This application is a CIP of 09/454,824 12/06/1999 ABN  
which is a CIP of 09/345,468 06/30/1999 PAT 6,245,527

o

#### Foreign Applications

If Required, Foreign Filing License Granted 04/05/2000

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

J. Chheda

Title

Glycoprotein VI and uses thereof

OCT 09 2002

1725

Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).